TGFβ1 Attenuates Expression of Prolactin and IGFBP-1 in Decidualized Endometrial Stromal Cells by Both SMAD-Dependent and SMAD-Independent Pathways

Nicole M. Kane1a, Marius Jones2, Jan J. Brosens2, Rodney W. Kelly1, Philippa T. K. Saunders1, Hilary O. D. Critchley3*

1 Medical Research Council Human Reproductive Sciences Unit, Centre for Reproductive Biology, Queen’s Medical Research Institute, Edinburgh, Scotland, United Kingdom, 2 Institute of Reproductive and Developmental Biology, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom, 3 Division of Reproductive and Developmental Sciences, Centre for Reproductive Biology, Queen’s Medical Research Institute, The University of Edinburgh, Edinburgh, Scotland, United Kingdom

Abstract

**Background:** Decidualization (differentiation) of the endometrial stromal cells during the secretory phase of the menstrual cycle is essential for successful implantation. Transforming Growth Factor β1 (TGFβ1) canonically propagates its actions via SMAD signalling. A role for TGFβ1 in decidualization remains to be established and published data concerning effects of TGFβ1 on markers of endometrial decidualization are inconsistent.

**Methodology/Principal Findings:** Non-pregnant endometrial stromal cells (ESC) and first trimester decidual stromal cells (DSC) were cultured in the presence or absence of a decidualizing stimulus. Incubation of ESCs with TGFβ1 (10 ng/ml) down-regulated the expression of transcripts encoding the decidual marker proteins prolactin (PRL), insulin-like growth factor binding protein-1 (IGFBP-1) and tissue factor (TF). TGFβ1 also inhibited secretion of PRL and IGFBP-1 proteins by ESCs and surprisingly this response preceded down-regulation of their mRNAs. In contrast, DSCs were more refractory to the actions of TGFβ1, characterized by blunted and delayed down-regulation of PRL, IGFBP-1, and TF transcripts, which was not associated with a significant reduction in secretion of PRL or IGFBP-1 proteins. Addition of an antibody directed against TGFβ1 increased expression of IGFBP-1 mRNA in decidualised cells. Knockdown of SMAD 4 using siRNAs abrogated the effect of TGFβ1 on expression of PRL in ESCs but did not fully restore expression of IGFBP-1 mRNA and protein.

**Conclusions/Significance:** TGFβ1 inhibits the expression and secretion of decidual marker proteins. The impact of TGFβ1 on PRL is SMAD-dependent but the impact on IGFBP-1 is via an alternative mechanism. In early pregnancy, resistance of DSC to the impact of TGFβ1 may be important to ensure tissue homeostasis.

Introduction

Decidualization, the process by which progesterone acts on the estrogen-primed endometrium to convert precursor stromal cells into decidual cells, is essential for successful implantation and maintenance of pregnancy (reviewed in [1,2,3]). The decidualization reaction is initiated in the perivascular stromal cells and under the influence of progesterone, spreads ‘wave-like’ throughout the stromal region. It is characterised by the phenotypic transformation of the elongated fibroblast-like endometrial stromal cells (ESC) into a larger, spherical decidual cell. This change in cell shape is associated with rearrangements in cellular architecture, the accumulation of glycogen and increased expression of prolactin (PRL) and insulin growth factor binding protein 1 (IGFBP-1) [4,5,6]. Studies using primary cultures of human endometrial stromal cells (ESCs) have revealed that this process is complex and likely to involve multiple factors including PGE2, relaxin and cAMP in addition to progesterone [4,7,8,9]. A strong association exists between the degree of trophoblast invasion and the extent of decidualization in species with a hemochorial placenta [10]. Not only does human trophoblast exhibit the greatest degree of trophoblast invasion observed in all species, but also human endometrium undergoes the most extensive decidualization reaction [11,12]. Decidualized stromal cells are temporally and spatially positioned to promote local homeostasis during implantation and counteract the threat of haemorrhage during trophoblast invasion [13]. Production of tissue factor by decidual cells is also thought to be important in
pregnancy to compare the TGF-β1 and decidualized stromal and epithelial cells for the effects of TGF-β1, which can diminish its signal from type II serine/threonine kinase transmembrane receptors to the nucleus through the Smads and the SMAD signaling cascade [19], might play a role in initiating the process of menstruation [19]. For example, expression of TGF-β1 is increased in stromal cells as they undergo decidualization [20, 21]. We have previously demonstrated that treatment of decidualized ESC with TGF-β1 suppresses expression of progesterone receptor (PR) suggesting that TGF-β1 may potentiate the effects of progesterone withdrawal [19]. In contrast, several studies have reported that TGF-β1 may increase expression of PRL in endometrial stromal cells (ESC) [21, 22].

An enhanced understanding of local mechanisms involved in the regulation of endometrial events preceding menstruation is an essential prerequisite for delineating the aetiology of early pregnancy complications as well as abnormal endometrial tissue activity associated with common gynaecological complaints such as heavy menstrual bleeding (HMB). In the current study we have complemented and extended our previous investigation [19] by investigating the possibility that local production of TGF-β1 within the endometrium plays a crucial role in triggering the process of menstruation in cells from non-pregnant endometrium by inhibiting biosynthesis and/or secretion of PRL, IGFBP-1 and TGF-β1 in a SMAD-dependent pathway. We have also examined the effects of TGF-β1 in cells obtained from early pregnancy to compare the TGF-β1 response between stromal cells decidualized in vitro and in vivo.

**Materials and Methods**

**Patients and tissue collection**

Human endometrial tissue specimens (n = 20; proliferative and secretory phase samples) were obtained from women undergoing surgery for benign gynaecological conditions. Written informed patient consent was provided prior to tissue collection. Local research ethical committee approval for the study was granted. Biopsies were collected with an endometrial suction curette (Pipelle, Laboratoire CCD, Paris, France) or alternatively, full thickness endometrial samples were obtained. These latter biopsies included superficial and basal endometrium plus the endometrial-stromal interface. The cells at the interface were collected; these consisted of uNKs, 5–15% CD14+ monocytes, and residual blood clots were removed. Approximately 10 g of the minced tissue was collected in 20 ml of RPMI 10% FCS and centrifuged at 710 g for 5 min. CD56+ bright uterine natural killer cells (uNKs). Briefly, decidual tissue was finely minced into 1 mm3 pieces and digested in collagenase (1 mg/ml; Sigma) and DNAase (0.1 mg/ml; Sigma) for 80 min at 37°C. Repeated passage through an 18 g needle was used to aid tissue dispersion. The tissue homogenate was re-suspended in 10 ml of RPMI 1640 medium (Sigma) and centrifuged (1700 rpm, 3 min). Cell pellets were then re-suspended in 10 ml of RPMI 1640 medium (Sigma) supplemented with 10% fetal calf serum (FCS) (Mycoplex, PAA Laboratories, Kingston-Upon-Thames, UK), penicillin (50 mg/ml; Sigma), streptomycin (50 mg/ml; Sigma) and gentamycin (5 mg/ml; Sigma) and the stromal cells were separated from endometrial glands by filtration through a 73 μm nylon sieve (Falcon, VWR International Ltd, Leicestershire, UK). The filtrate, containing the primary ESC, was plated in 75 cm2 culture flasks (Corning Incorporator, Corning, NY) for a minimum period of 5 days and allowed to reach confluence.

**Isolation of stromal cells from non-pregnant endometrium**

Endometrial specimens (n = 21) were separated into epithelial and stromal cell preparations by enzymatic digestion as previously described [19]. Briefly, specimens were washed in Dulbecco’s Phosphate Buffered Saline (Sigma), minced into 1 mm3 pieces and digested in collagenase (1 mg/ml; Sigma) and DNAase (0.1 mg/ml; Sigma) for 80 min at 37°C. Repeated passage through an 18 g needle was used to aid tissue dispersion. The tissue homogenate was re-suspended in 10 ml of RPMI 1640 medium (Sigma) and centrifuged (1700 rpm, 3 min). Cell pellets were then re-suspended in 10 ml of RPMI 1640 medium (Sigma) supplemented with 10% fetal calf serum (FCS) (Mycoplex, PAA Laboratories, Kingston-Upon-Thames, UK), penicillin (50 mg/ml; Sigma), streptomycin (50 mg/ml; Sigma) and gentamycin (5 mg/ml; Sigma) and the stromal cells were separated from endometrial glands by filtration through a 73 μm nylon sieve (Falcon, VWR International Ltd, Leicestershire, UK). The filtrate, containing the primary ESC, was plated in 75 cm2 culture flasks (Corning Incorporator, Corning, NY) for a minimum period of 5 days and allowed to reach confluence.

**Isolation of stromal cells from 1st trimester deciduas**

All decidual samples were processed to remove both glandular material and deplete them of CD56+ bright uterine natural killer cells (uNKs). Briefly, decidual tissue was finely minced into 1 mm3 pieces and digested in collagenase (1 mg/ml; Sigma) and DNAase (0.1 mg/ml; Sigma) for 1 h 20 min on a roller at 37°C. After digestion, 30 ml of RPMI 10% FCS was added and the mixture was left to stand for 5 min to allow sedimentation. The supernatant was decanted by aspiration and passed sequentially through 73 μm and 40 μm filters (VWR). The filtrate was centrifuged at 400 g for 5 min and the resulting cell pellet was re-suspended in 15 ml of PBS supplemented with 2% FCS and 0.1% NaNO3 and subsequently overlaid onto 15 ml of LymphoprepTM (Axis-Shield, Oslo, Norway) before further centrifugation at 710 g for 20 min with no brake. The cells at the interface were collected; these consisted of 70–80% uNKs, 4–15% CD14+ macrophages, 10–20% T cells as well as stromal and epithelial cells. Cells were washed in 20 ml of RPMI 10% FCS and centrifuged at 710 g for 5 min. CD56+ bright uNKs were removed by positive selection using CD56 antibody-coated magnetic Microbeads as previously described [24]. The remaining cells were transferred to a 75 cm2 cell culture flask in 10 ml of RPMI 10% FCS and incubated at 37°C in a humidified atmosphere of 5% CO2. After 24 h the media was changed non-adherent cells were discarded and the adherent decidualized stromal cells (DSCs) were allowed to attain confluence and used for experimentation at first passage.
In vitro primary cell culture experiments

ESCs and DSCs were maintained at 37°C in 5% (v/v) CO2 in RPMI 1640 medium (Sigma) supplemented with 2% FCS (Mycopex), penicillin (50 μg/ml; Sigma), streptomycin (50 μg/ml; Sigma) and gentamycin (5 μg/ml; Sigma). The cells were seeded in 6-well plates at a concentration of 2.5 × 10^4 cells/ml and allowed to adhere and attain 90% confluence. Supernatant was changed every 3 days. Decidualization of the cells was induced in decidualization medium (DM) consisting of RPMI 1640 medium containing 2% FCS, 3′,5′-cyclic monophosphate sodium salt (0-Brc-cAMP) (0.5 mM; Sigma) and 6β-Methyl-17α-acetoxyprogesterone (MPA) (1 μM) for 6 days. Following decidualization cells were incubated in 2% FCS RPMI 1640 and DM containing TGFβ1 (R&D Systems, Abingdon, UK) for up to 72 h.

Targeted knockdown of SMAD 4

Two HP GenomeWide siRNA duplexes to SMAD 4 (Genbank accession no. NM_005359) were purchased from Qiagen (Crawley, United Kingdom); SMAD 4-1 (5′- AGACGACGGTCACTTGACATCCTACCTAA-3′); SMAD 4-2 (5′- CCCTGTTAAACAGTAGTGTGTA-3'). An additional siRNA (Qiagen), targeting MAPK (5′- AATTCGCTACCTGAAAGCTCTG-3') and a non-silencing control (5′- AAATTCGCTACCTGAAAGCTGTCTCAGT-3') were used in all experiments (Qiagen). In addition, a negative control duplex (5′-AATTCGCTACCTGAAAGCTGTCTCAGT-3') labelled with Alexa Fluor 488 (Qiagen) was used to monitor transfection efficiency. Cells were transfected with siRNA duplexes using HiPerfect transfection reagent (Qiagen). All experiments were performed in duplicate using cells in 6-well culture dishes at 70% confluence [19]. Cells were decidualized in vitro for 36 h, washed twice with PBS, transfected with duplexes (5 nM) and incubated in RPMI supplemented with 10% FCS for a further 24 h. Thereafter, cells were treated with DM and TGFβ1 (10 ng/ml) for 72 h. Following treatment; conditioned medium was removed and analysed for IGFBP-1 and PRL protein levels by ELISA and time-resolved fluorimunoassy respectively (see below). In parallel, mRNA was prepared and analysed by Q-RT-PCR.

Taqman Quantitative Real Time PCR (Q-RT-PCR)

RNA was extracted from cells in Tri reagent (ABgene House, Surrey, UK); RNA samples were reverse transcribed using random hexamers. Gene-Specific Primers and Probes were designed using Primer Express software (PerkinElmer/ Applied Biosystems, Cheshire, UK); PRL Forward: 5′- GCCCCCAGGA-GGCTATCCTA-3′, dPRL Reverse, 5′-TCAGCTCCATGCCCTCTAGAA-3′, dPRL Probe ‘5′-CCAAAGCTGTAGAGATTGGCTATCCTA-3′, IGFBP-1 Forward: 5′-CAGAGGAGCATCAGGAGAGAAA-3′, IGFBP-1 Reverse: 5′-ACACTGTCTGTGCTTGATACATCCTGCTGATAAATCTCATC-3′, IGFBP-1 Probe: 5′-TTCCAAATTTTACCTGCTGAAAACTCTGAAAGA-3′. Tissue Factor Forward: 5′-CAC CGA CGA GAT TGT GAA GAA-3′, Tissue Factor Reverse; 5′-CCCC TGC CGG GTA GAA GAA-3′, Tissue Factor Probe: 5′-TGA AGC AGA CGT ACT TGG CAC GGG T-3′. Primers were diluted to 250 mM and probes to 50 μM in TE buffer (10 mM Tris; 1 mM EDTA; 1 mM MgCl2; 1.6 mM Stratagene dNTP mix; 1.6 mM Boehringer dNTP mix; 0.05 U/μl Taq Polymerase; 2x PCR buffer and 0.06% reference dye diluted in Depc H2O) and specific forward and reverse primers (250 nM; Biosource, Nivelles, Belgium) and probe (50 nM; Biosource) in a final volume of 25 μl/well. Ribosomal 18S primers and probe (PE Biosystems, Warrington, UK) were added at a final concentration of at 50 nM. PCR reactions were run on ABI Prism 7900 (Applied Biosystems). Samples were measured in duplicate and mean values were used in subsequent analysis. Relative quantification was achieved using the formula 2^ΔΔCt, which relates the amount of cDNA of the specific amplicon to the 18S internal control and the control cDNA.

Enzyme-Linked Immunosorbent Assay (ELISA)

Culture supernatants were stored at −20°C until assayed. Prolactin (PRL) release was measured by a DELFIA® Prolactin time-resolved fluorimunoassy kit (PerkinElmer Life Sciences). The fluorimunoassy was a solid phase, two-site assay based on the direct sandwich technique. The fluorescence of each sample is proportional to the concentration of PRL in the media sample and was measured on a time-resolved fluorometer, VICTOR™ 1420 Multilevel Counter (Wallac, PerkinElmer LAS (UK) Ltd, Beaconsfield, UK). The concentration of PRL was determined by interpolation from a standard curve prepared from the PRL standards. The assay was conducted according to the manufacturer’s protocol. All samples from each experiment were analysed in the same assay in order to preclude inter-assay variability.

Statistical Analysis

Prior to any statistical analysis data were tested for and shown to exhibit Gaussian distribution. Gaussian distribution was determined by applying the Shapiro-Wilk normality test to the data. Where appropriate, values were presented as means ± S.E.M. Comparison of the different parameters for the various treatment groups was determined by repeated measures analysis of variance (ANOVA). Significant differences were assigned using Kruskal-Wallis post hoc test. The criterion for significance for all tests was set at p < 0.05. Specific software was used to assist in the data analysis (GraphPad Prism v4.0b for Macintosh, GraphPad Software, San Diego, USA).

Results

TGFβ1 down-regulates the production of decidualization markers

To determine the impact of TGFβ1 on decidualization, primary human ESC (n = 8, endometrial samples) were decidualized in vitro for 6 days and then further treated with DM in the presence or absence of TGFβ1 (10 ng/ml) for 72 h. Incubation of decidualized ESC with TGFβ1 down-regulated the expression of IGFBP-1 mRNA in a time-dependent manner with a significant decrease observed at 48 h (p < 0.01) and 72 h (p < 0.001), as compared to time-matched controls (Figure 1A). In contrast a significant decrease in the amount of IGFBP-1 protein released from the cells was detected after only 2 h incubation with TGFβ1 and the amounts declined further during the rest of the experiment (12 h, 24 h, 48 h and 72 h, Figure 1B; all p < 0.001). Treatment of cells with TGFβ1 was also associated with a significant decrease in
intracellular concentrations of PRL mRNA (Figure 1C) and the amount of PRL released into the culture media (Figure 1D).

Notably the patterns of expression closely paralleled those observed for IGFBP with significant inhibition of mRNA levels observed at 48 h (p < 0.001) and 72 h (p < 0.001) but a reduction in release of PRL into the medium after only 2 h of TGFβ1 treatment (p < 0.05) (Figure 1D). Treatment of decidualized ESC with TGFβ1 also reduced the amount of tissue factor mRNA, with significant suppression of mRNA levels observed at 24 h (p < 0.05), 48 h (p < 0.001) and 72 h (p < 0.001) (Figure 1E).

Figure 1. TGFβ1 inhibited expression of decidualization markers when ESC were decidualized in the presence or absence of TGFβ1 for up to 72 h. A: TGFβ1 reduced expression of mRNA IGFBP-1 in a time dependent manner, 48 h, p < 0.01, 72 h, p < 0.001. 1.0 = absolute value of ΔCT = 12. B: TGFβ1 inhibited release of IGFBP-1 protein release after only 2 h of treatment (p < 0.001) and this continued to decline in a time-dependent manner (all time points p < 0.001). C: TGFβ1 inhibited expression of PRL mRNA in a time dependent manner, 48 h (p < 0.01), 72 h (p < 0.001). 1.0 = absolute value of ΔCT = 11. D: TGFβ1 inhibited PRL protein release after only 2 h of treatment (p < 0.001) and this was sustained for up to 72 h (2 h, p < 0.01, 24 h, p < 0.05, 48 h and 72 h, p < 0.01). E: TGFβ1 inhibited expression of TF mRNA in a time dependent manner; 24 h (p < 0.05), 48 h (p < 0.001), 72 h (p < 0.001). 1.0 = absolute value of ΔCT = 14. Data are mean ± S.E.M; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control. n = 8 endometrial samples (in triplicate).

doi:10.1371/journal.pone.0012970.g001

Anti-TGFβ1 neutralizing antibody negates TGFβ1 inhibition of gene expression

hESC (n = 6 endometrial samples) were decidualized in vitro for 6 days then cultured in DM in with TGFβ1 (10 ng/ml) or an anti-TGFβ1 antibody (1 μg/ml) for a period of 72 h. As detailed above incubation with TGFβ1 significantly reduced the amount of PRL (p < 0.05, Figure 2A) and IGFBP-1 (p < 0.001, Figure 3B) mRNAs. We have previously demonstrated that decidualization of hESC is associated with biosynthesis of TGFβ1 [19]; in the current experiments addition of anti-TGFβ1 antibodies maintained
expression of PRL mRNA (Figure 2A) and significantly potentiated expression of IGFBP-1 mRNA in comparison with ESCs treated with DM alone (*p<0.001, Figure 2B).

**TGFβ1 suppresses the expression and release of PRL, IGFBP-1 and TF by cells obtained from first trimester decidua**

In order to determine whether incubation with TGFβ1 had a similar impact on primary DSC to hESC incubated in vitro, cells were obtained from decidua recovered from pregnancies of <10 wks gestation. Incubation with TGFβ1 for up to 72 h (n = 7) resulted in a significant reduction in the amount of IGFBP-1 mRNA (Figure 3A, **p<0.05,** PRL mRNA (**p<0.001,** Figure 3C) and TF mRNA (**p<0.05,** Figure 3E) at 72 h as compared to unstimulated, time-matched controls (Figure 3). Notably in contrast to the results obtained with decidualized hESC incubation of DSC with TGFβ1 had no significant impact on the release of IGFBP-1 or PRL protein (Figure 3, B and D).

**TGFβ1 attenuates the expression and release of PRL in a SMAD 4-dependent manner**

So as to determine whether the impact of TGFβ1 on expression and release of IGFBP-1 and PRL was mediated by the SMAD signalling pathway, cells were transfected with SMAD 4-specific siRNAs, a siRNA directed against MAPK (a pre-validated control siRNA) or RNA of an unrelated sequence. Western blotting was used to confirm >90% reduced expression of SMAD 4 (and MAPK) in cells transfected with the sequence specific siRNAs (data not shown). Targeted knockdown of SMAD 4 in decidualized ESCs using two independent siRNAs (n = 5) had no significant impact on the TGFβ1-dependent decrease in concentrations of IGFBP-1 mRNA (Figure 4A) and release of IGFBP-1 protein remained significantly depressed in all cells treated with TGFβ1 regardless of the addition of any of the siRNAs (Figure 4B). In contrast, targeted knockdown of SMAD 4 prevented the TGFβ1-dependent decrease in expression of PRL mRNA (Figure 4C) and the amount of PRL released (Figure 4D) remained at control levels; the amount of PRL released by cells transfected with an siRNA directed against MAPK was similar to that released by cells incubated with TGFβ1 alone.

**Discussion**

In the present study we have demonstrated that TGFβ1 reduces the expression and secretion of PRL, IGFBP-1, and TF by human ESCs decidualized in vitro, as well as primary DSCs obtained from 1st trimester decidua. Notably the latter appeared more refractory to the treatment. Targeted knockdown of SMAD 4, the protein which translocates phosphorylated SMAD members to the nucleus mediating the transcriptional downstream biological actions of TGFβ1, [18] revealed that the impact of TGFβ1 on expression and release of IGFBP1 was SMAD independent. In contrast inhibition of PRL protein release was SMAD-dependent demonstrating that TGFβ1 can act via more than one signalling pathway in this cell type.

Previous studies have reported that TGFβ1 can alter expression of decidual proteins although impacts on endometrial decidualization have been inconsistent. To our knowledge the current study reports the first data directly comparing the response to TGFβ1 in cells decidualized in vitro with primary cells recovered from decidua i.e. those exposed to the presence of a blastocyst. Primary ESCs, obtained from non-pregnant endometrium and decidualized in vitro, are considered a model for cells that decidualize during the non-pregnant menstrual cycle. In primary ESCs we demonstrated incubation of cells with TGFβ1 reduced both the concentrations of IGFBP-1 and PRL mRNAs as well as the amounts of these proteins secreted into the culture media. The findings in the current study are in agreement with a number of studies reporting a marked inhibitory effect of TGFβ1 on basal and stimulated PRL secretion, mRNA levels and de novo PRL synthesis in rat anterior pituitary cells [25], decidual cells from 1st trimester [26] and term pregnancy [27]. However in contrast to the current findings, it has been reported that TGFβ1 can potentiate the decidualization process in ESCs with increased production of PRL independent of the presence of progesterone [21,22]. With a further study reporting a TGFβ1-dependent increase in expression of PRL in ESCs [28] although these cells were not exposed to a decidualization stimulus. One limitation to our study is that all the
decidual markers we examined are also regulated by progesterone. As we have cultured all our cells in the presence of MPA (decidualization stimulus) we are unable to reject the possibility that augmentation of the decidual markers is occurring as an indirect consequence of TGFβ1 mediated suppression of PR expression [19]. Interestingly, we detected a very rapid reduction in protein release for both IGFBP-1 and PRL in ESCs that preceded any reduction in total concentrations of the mRNAs. This would suggest that TGFβ1 might also be repressing translation/export of proteins or could be modulating expression of tissue-specific microRNAs (miRNAs), short nucleotide sequences involved in post-transcriptional gene regulation that have been implicated in endometrial function [29,30]. However, no direct association between TGFβ1 and recently identified menstruation-specific miRNAs has been identified [31] and these suggestions therefore remain speculative. The impact of TGFβ1 on functional activity and differentiation of ESC during the normal cycle may also extend beyond the impact on decidualization as studies using primary ESC reporting that TGFβ1 down-regulates PR expression [19] and inhibits cell proliferation and migration [32]. Together with evidence detailing that in vivo TGFβ1 expression is increased at menstruation [33], and TGFβ1 can induce contrac-

Figure 3. TGFβ1 suppresses expression and release of markers of decidualization by cells from 1st trimester decidua. A: TGFβ1 reduced expression of IGFBP-1 mRNA after 72 h treatment. (p < 0.05) 1.0 = absolute value of ΔCT = 12.2. B: TGFβ1 was without significant effect on protein release of IGFBP-1. C: TGFβ1 reduced expression of PRL mRNA after 72 h treatment (p < 0.001). 1.0 = absolute value of ΔCT = 11.5. D: TGFβ1 was without significant effect on PRL protein release, although did display a trend toward inhibition. E: TGFβ1 reduced expression of TF mRNA after 72 h treatment (p < 0.05). 1.0 = absolute value of ΔCT = 13.75. Data are mean ± S.E.M; * p < 0.05; *** p < 0.001 vs. no TGFβ1 treatment. n = 7 decidual samples (in triplicate).

doi:10.1371/journal.pone.0012970.g003
tion of decidualized stromal cells [34] it has been proposed that TGFβ1 may play a role in the onset of menstruation in normal cycling endometrium. Furthermore, aberrant expression of TGFβ1 may contribute to menstrual disorders, such as heavy menstrual bleeding and painful menstruation, by modifying local haemostatic mechanisms (reviewed in [35]).

To determine if decidualized stromal cells would respond to TGFβ1 in the same manner as primary ESCs that were decidualized in vitro, we isolated stromal cells from first trimester decidua. Although, the present studies have demonstrated that TGFβ1 markedly inhibits the expression of PRL, IGFBP-1, and TF mRNAs in DSCs this inhibition was delayed by at least 24 h when compared to the response observed in ESC. Furthermore, this inhibitory effect at the level of mRNA was not reflected by a reduction in mature protein secretion of PRL and IGFBP-1 by DSC, implying that decidualization in vivo, confers some resistance to the actions of TGFβ1. The findings in the current study are in agreement with studies reporting that TGFβ1 inhibited both IGFBP-1 and PRL production in a time-dependent manner in decidual cells from 1st trimester [26,36] and term pregnancy [27]. However, the effect of TGFβ1 on PR expression in DSCs remains unknown making it difficult to interpret the results in terms of direct effects of TGFβ1 on DSCs as opposed to an indirect effect via suppression of PR [19]. It may be that the presence of a blastocyst and increasing concentrations of hCG in the first trimester of pregnancy evokes an increase in cellular protection against potentially harmful cytokines and growth factors. Alternatively, the role of TGFβ1 in pregnant endometrium could differ

**Figure 4. TGFβ1 attenuates expression and release of prolactin in a SMAD-dependent manner.** Incubation with TGFβ1 (10 ng/ml; 72 h) significantly reduced expression of mRNAs encoding IGFBP-1 and PRL (p<0.001 IGFBP1; graph A 1.0 = absolute value of ΔCT = 12.2, p<0.05 PRL; graph C 1.0 = absolute value of ΔCT = 11) and the amount of each of these proteins recovered from culture media (p<0.001 IGFBP1, graph B, p<0.01 PRL, graph D) after incubation of decidualized ESCs for 72 h. Depletion of SMAD 4 using two independent target-specific siRNAs had no significant impact on the TGFβ1-dependent reduction in IGFBP-1 mRNA or protein (graphs A 1.0 = absolute value of ΔCT = 12.2, B) but reversed the reduction in PRL mRNA (p<0.001, graph C 1.0 = absolute value of ΔCT = 11.25) and protein (p<0.01, graph D) induced by treatment. No response was observed with cells depleted of MAPK siRNA. Data are mean ± S.E.M; * p<0.05, ** p<0.01, *** p<0.001 vs. TGFβ1 alone. n = 5 endometrial samples (in triplicate).

doi:10.1371/journal.pone.0012970.g004
from that in non-pregnant, pre-menstrual endometrium. This view is supported by data reporting high expression of TGFβ1 in first trimester decidua without any detrimental effect on pregnancy [37,39,39]. Aberrant increases in active TGFβ1 during early pregnancy may be detrimental as a consequence of inadequate decidualization of the endometrium.

To determine if TGFβ1 was conferring its actions via its canonical signalling cascade we interrogated the common mediator of all SMAD signal transduction, SMAD 4 [40]. We have demonstrated via knockdown of SMAD 4 that TGFβ1-induced suppression of IGFBP-1 is not SMAD-dependent and these data suggest that TGFβ1 is mediating its effects via an alternative pathway or an indirect mechanism, as has been suggested previously [41]. This may include the involvement of Wnt signalling pathways as previous reports have shown that progesterone-dependent changes in expression of the Wnt antagonist DKK parallel changes in secretion of IGFBP-1 protein [42]. This report was complemented by our own study demonstrating that TGFβ1 inhibits expression of DKK-1 mRNA in a SMAD-independent manner [19]. In contrast TGFβ1-specific down regulation of expression of PRL was SMAD-dependent and the impact of TGFβ1 was reversed in cells transfected with SMAD-4 specific si-RNAs. This finding would be consistent with previous reports demonstrating that activin-dependent inhibition of expression of PRL in the pituitary is mediated by the SMAD signalling pathway [43]. Other studies reporting conflicting results to our own have also demonstrated a role for SMAD signalling in propagating TGFβ1 actions [22,28], with the authors claiming that both ERK and SMAD dependent signalling may play a role in the TGFβ1-dependent increase in expression of PRL in ESC [28]. However, in contrast, the impact of TGFβ1 in our decidualized cells appeared to be independent of expression of MAPK. It is likely that TGFβ1 may be evoking responses in genes that are not normally associated with decidualization e.g induction of smooth muscle actin α (Kane et al, unpublished observations); however genome-wide transcriptional profiling is beyond the scope of this research.

In summary, the findings presented in the current study have demonstrated that TGFβ1 is capable of suppressing expression and secretion of decidualization marker proteins via both SMAD-dependent and independent mechanisms. Our findings support the hypothesis that local TGFβ1 signalling may coordinate de-differentiation of endometrial stromal compartment and tissue remodelling associated with menstruation, but raise the possibility that this factor may play a different role in the pregnant endometrium.

Acknowledgments

The authors wish to thank Catherine Murray and Sharon McPherson for patient recruitment, obtaining informed consent and for collection of tissue samples.

Author Contributions

Conceived and designed the experiments: RWK HC. Performed the experiments: NK. Analyzed the data: NK. Contributed reagents/materials/analysis tools: MJ JJB. Wrote the paper: NK PTS HC.

References

1. King A (2000) Uterine leukocytes and decidualization. Human Reproduction Update 6: 28–36.
2. Lessey BA (2000) Endometrial receptivity and the window of implantation. Bailliere’s Clinical Obstetrics and Gynaecology 14: 775–786.
3. Critchley HO, Saunders PT (2009) Hormone receptor dynamics in a receptive human endometrium. Reprod Sci 16: 191–199.
4. Brosens JJ, Hayashi N, White JO (1999) Progesterone receptor regulates deciduomal prolactin expression in differentiating human endometrial stromal cells. Endocrinology 140: 4089–4098.
5. Dunn CL, Kelly RW, Critchley HO (2003) Decidualization of the human endometrial stromal cell: an enigmatic transformation. Reprod Biomed Online 7: 151–161.
6. Gellersen B, Brosens IA, Brosens JJ (2007) Decidualization of the human endometrium: mechanisms, functions, and clinical perspectives. Semin Reprod Med 25: 445–453.
7. Lane B, Osbervy W, Mazella J, Tseng L (1994) Decidualization of human endometrial stromal cells in vitro: effects of progesterin and relaxin on the infrastructure and production of decidual secretory proteins. Hum Reprod 9: 259–266.
8. Gellersen B, Brosens JJ (2003) Cyclic AMP and progesterone receptor cross-talk in human endometrium: a decidualizing affair. J Endocrinol 178: 357–372.
9. Dimitriadis E, Stoikos C, Baca M, Fairlie WD, McCoubrie JE, et al. (2005) Relaxin and prostaglandin E2 regulate interleukin 11 during human endometrial stromal cell decidualization. J Clin Endocrinol Metab 90: 3458–3465.
10. Finn CA (1996) Why do women menstruate? Historical and evolutionary review. Eur J Obstet Gynecol Reprod Biol 70: 3–8.
11. Ramsey EM, Houston ML, Harris JW (1976) Interactions of the trophoblast and maternal tissues in three closely related primate species. Am J Obstet Gynecol 124: 647–652.
12. Bell SC (1998) Assessment of endometrial differentiation and function. Br Med Bull 46: 720–735.
13. Lockwood CJ, Kriegan G, Schatz F (1999) The determination regimen of gestosis in human endometrium. Semin Reprod Endocrinol 17: 45–51.
14. Kriegan G, Lockwood CJ, Pataas MJ (2009) Tissue factor and the endometrium: from physiology to pathology. Thromb Res 124: 593–596.
15. Singer CF, Marbaix E, Korkorine I, Lemoine P, Donnez J, et al. (1997) Paracrine stimulation of interstitial collagenase (MMP-1) in the human endometrium by interleukin alpha and its dual block by ovarian steroids. Proc Natl Acad Sci USA 94: 1041–1045.
16. Crabtree JS, Peano BJ, Zhang X, Komm BS, Winneker RC, et al. (2008) Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol.
29. Pan Q, Chegini N (2008) MicroRNA signature and regulatory functions in the endometrium during normal and disease states. Semin Reprod Med 26: 479–493.

30. Pan Q, Luo X, Chegini N (2008) Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med 12: 227–240.

31. Hanson EK, Lubenow H, Ballantyne J (2009) Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs. Anal Biochem 387: 303–314.

32. Nasu K, Iwaki M, Matsumoto H, Bing S, Inoue C, et al. (2005) Regulation of proliferation, motility, and contractility of cultured human endometrial stromal cells by transforming growth factor-beta isoforms. Fertil Steril 84(Suppl 2): 1114–1123.

33. Gaide Chevronnay HP, Cornet PB, Delvaux D, Lemoine P, Courtoy PJ, et al. (2008) Opposite regulation of transforming growth factors-beta2 and -beta3 expression in the human endometrium. Endocrinology 149: 1015–1025.

34. Kimatrai M, Oliver C, Abadia-Molina AC, Garcia-Pacheco JM, Olivares EG (2003) Contractile activity of human decidual stromal cells. J Clin Endocrinol Metab 88: 844–849.

35. Omwandho CO, Konrad L, Halis G, Oehmke F, Tinneberg HR (2009) Role of TGF-(beta)s in normal human endometrium and endometriosis. Hum Reprod.

36. Kubota T, Taguchi M, Kobayashi K, Masuda M, Aso T (1997) Relationship between the release of prolactin and endothelin-1 in human decidualized endometrial cells. Eur J Endocrinol 137: 200–204.

37. Lysiak JJ, Hunt J, Pringle GA, Lala PK (1995) Localization of transforming growth factor beta and its natural inhibitor decorin in the human placenta and decidua throughout gestation. Placenta 16: 221–231.

38. Jokhi PP, King A, Loke YW (1997) Cytokine production and cytokine receptor expression by cells of the human first trimester placenta-uterine interface. Cytokine 9: 126–137.

39. Simpson H, Robson SC, Bulmer JN, Barber A, Lyall F (2002) Transforming growth factor beta expression in human placenta and placental bed during early pregnancy. Placenta 23: 44–54.

40. Zhang Y, Musci T, Derynck R (1997) The tumor suppressor SMAD 4/DPC 4 as a central mediator of Smad function. Curr Biol 7: 270–276.

41. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577–584.

42. Tulac S, Nayak NR, Kao LC, Van Waes M, Huang J, et al. (2003) Identification, characterization, and regulation of the canonical Wnt signaling pathway in human endometrium. J Clin Endocrinol Metab 88: 3860–3866.

43. Hendy GN, Kaji H, Sowa H, Lebrun JJ, Canaff L (2005) Menin and TGF-beta superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast. Horm Metab Res 37: 373–379.